Structure Therapeutics Inc. has initiated a Phase 1 clinical study of its lead oral small molecule, ACCG-2671, aimed at treating obesity. The announcement, made on December 17, 2025, marks a significant step for the clinical-stage biopharmaceutical company based in San Francisco, which specializes in developing innovative therapeutics for metabolic diseases.
Innovative Approach to Obesity Treatment
ACCG-2671 is an amylin receptor agonist designed using Structure Therapeutics’ advanced structure-based drug discovery platform. This platform focuses on harnessing the metabolic benefits associated with amylin biology in an oral formulation that can be taken once daily. The company aims to enhance scalability, combinability, and patient access with this new treatment approach.
“We believe amylin-based therapies are poised to become an important next-generation component of the treatment landscape for obesity and related conditions,” stated Xichen Lin, Ph.D., Chief Scientific Officer of Structure Therapeutics. He highlighted that ACCG-2671 represents the industry’s most advanced oral small molecule amylin therapy, reflecting the efficacy of their innovative drug discovery methods.
Clinical Potential and Preclinical Success
Preclinical studies of ACCG-2671 have shown promising results, including significant weight loss as a standalone treatment and enhanced efficacy when combined with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The drug has also demonstrated a favorable safety profile and pharmacokinetics suitable for once-daily dosing, positioning it as a potential backbone therapy for obesity management.
Structure Therapeutics is committed to advancing ACCG-2671 through clinical trials to validate its effectiveness and safety in humans. The initiation of this study represents a hopeful advancement in the ongoing battle against obesity, a condition that affects millions worldwide.
As the study progresses, the company aims to provide further insights into the therapeutic benefits of ACCG-2671, potentially reshaping treatment strategies for those struggling with obesity and related metabolic disorders.